Changes this week
Changes detected in the 7 days to Nov 21, 2026
- Minor: Subthreshold SCS or BMT Primary and study completion pushed from Aug 2026 to Dec 2026
- Minor: Performance of Bioactive Bulk-Fill in Class II Restorations Primary completion pushed from Jun 30, 2027 to Nov 30, 2027
- Minor: Myofascial Exercise and Trigger Point Therapy for Non-Specific Low Back Pain Primary completion pushed from Oct 30, 2026 to Nov 30, 2026
- Minor: Transversalis Fascia Plane Block Versus Low-Dose Intrathecal Morphine for Open Inguinal Hernia Repair Primary completion pushed from Oct 23, 2026 to Dec 1, 2026
- Minor: Arterial Stiffness · Breast Cancer Primary and study completion dates pushed to Mar 1, 2027
- Minor: Exercise Intervention for Breast Cancer · Sarcopenia Primary and study completion pushed from May 30, 2027 to Aug 30, 2027
- Minor: Usability of a Chest-Strap Ambulatory ECG Monitor in Active Individuals in Comparison With a Traditional Ambulatory ECG Patch Monitor (MoMe ARC) Primary completion pushed from Feb 23, 2027 to Apr 23, 2027
- Minor: RCT Study on the Effect of ETN on Live Birth Rate in DOR Patients Undergoing IVF-ET Primary completion pushed from Feb 1, 2031 to Apr 1, 2031
- Minor: Efimosfermin Compared With Placebo · Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH) Trial sites expanded: 30 → 37 locations
- Minor: Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) · Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Trial sites expanded: 133 → 138 locations
- Minor: GSK5784283 (Felcorekibart) Compared With Placebo · Moderate to Very Severe COPD (PERSIST COPD-1) Trial sites expanded: 7 → 11 locations
- Minor: InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation Trial sites expanded: 121 → 293 locations
- Minor: Lunsekimig Compared With Placebo · Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype Trial sites expanded: 314 → 322 locations
- Minor: Giroctocogene Fitelparvovec or Fidanacogene Elaparvovec · Hemophilia A or B Respectively Trial sites expanded: 39 → 44 locations
- Minor: Intratumoral INT230-6 Compared to US Standard of Care · Soft Tissue Sarcomas (INVINCIBLE-3) Trial sites expanded: 17 → 20 locations
- Minor: Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta Trial sites expanded: 4 → 9 locations
- Minor: Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04) Trial sites expanded: 11 → 18 locations
- Minor: Lunsekimig · Chronic Obstructive Pulmonary Disease (COPD) Trial sites expanded: 8 → 16 locations
- Minor: EYE201/MK-8748 · Macular Degeneration (MK-8748-003) Trial sites expanded: 71 → 121 locations
- Minor: Confirm Efficacy of a Single Dose of Baloxavir Marboxil in the Post-exposure Prophylaxis (PEP) of Influenza Virus Infection in Chinese Participants Trial sites expanded: 8 → 20 locations
- Minor: SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) Trial sites expanded: 61 → 75 locations
- Minor: ALKS 2680 · Narcolepsy Type 2 Trial sites expanded: 44 → 61 locations
- Minor: EloraTZP · Obesity Without Type 2 Diabetes Trial sites expanded: 155 → 161 locations
- Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Breast Cancer (MK-2870-032) Trial sites expanded: 335 → 338 locations
- Minor: Sacituzumab Tirumotecan (Sac-TMT, MK-2870) · Urothelial Cancer (MK-2870-031) Trial sites expanded: 111 → 117 locations
- Stopped: terminated, suspended or withdrawn
- Notable: the plan changed
- Minor: routine updates